Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01656642
Title A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications

melanoma

Therapies

Atezolizumab + Cobimetinib + Vemurafenib

Atezolizumab + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST